FrancophonIA/ELRC3.0 huggingface dataset:
English: The CHMP noted that Nulojix does not have the toxic effects on the kidneys seen with other immunosuppressive medicines commonly used in transplantation.
Danish: CHMP bemærkede, at Nulojix ikke har den toksiske virkning på nyrerne, der ses med andre immunsuppressive lægemidler, som almindeligvis anvendes ved transplantation.
English: All patients were also treated with corticosteroids, mycophenolic acid, and basiliximab (an interleukin-2 receptor antagonist) during the first week after transplantation.
Danish: Alle patienter blev også behandlet med kortikosteroider, mycophenolsyre og basiliximab (en interleukin-2-receptorantagonist) i løbet af den første uge efter transplantationen.
English: This is because patients treated with Nulojix who have had no previous exposure to the virus are at higher risk of getting a type of cancer known as post-transplant lymphoproliferative disorder.
Danish: Dette skyldes, at patienter, som behandles med Nulojix, og som ikke tidligere har været eksponeret for virussen, har en forhøjet risiko for at få en type kræft, der hedder post-transplantation lymfoproliferativ sygdom.
English: Nulojix must not be used in patients who have not been exposed to the Epstein-Barr virus or in whom previous exposure is uncertain.
Danish: Nulojix må ikke anvendes til patienter, der ikke har været eksponeret for Epstein-Barr-virus, eller hvis tidligere eksponering for denne virus er usikker.
English: Overall, the benefits of Nulojix compared well with the comparator medicine.
Danish: Overordnet set svarede fordelene ved Nulojix godt til sammenligningslægemidlets fordele.
English: Nulojix should only be prescribed and supervised by a doctor who has experience in the management of kidney transplant patients.
Danish: Nulojix bør kun ordineres og overvåges af en læge, der har erfaring med behandling af nyretransplanterede patienter.
English: It is used with corticosteroids and a mycophenolic acid (other medicines used to prevent organ rejection).
Danish: Det anvendes sammen med kortikosteroider og en mycophenolsyre (andre lægemidler, der bruges til at forhindre organafstødning).
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Nulojix, including the appropriate precautions to be followed by healthcare professionals and patients.
Danish: På baggrund af denne er der anført sikkerhedsoplysninger i produktresuméet og indlægssedlen for Nulojix, herunder passende forholdsregler, som patienter og sundhedspersonale skal følge.
English: In addition, the company that makes Nulojix will include an alert card in each medicine's pack to increase awareness of the benefits and risks with Nulojix.
Danish: Desuden vil den virksomhed, der fremstiller Nulojix, vedlægge hver lægemiddelpakning et advarselskort med oplysninger om fordelene og risiciene ved Nulojix.
English: The CHMP therefore concluded that Nulojix's benefits are greater than its risks and recommended that it be given marketing authorisation.
Danish: CHMP konkluderede derfor, at fordelene ved Nulojix er større end risiciene, og udvalget anbefalede udstedelse af markedsføringstilladelse for Nulojix.
English: An interleukin-2 receptor antagonist medicine should also be used with Nulojix during the first week after the kidney transplant.
Danish: Der bør ligeledes anvendes en interleukin-2-receptorantagonist i kombination med Nulojix den første uge efter nyretransplantationen.
English: The proportion of patients who had an episode of organ rejection within one year was 17% for Nulojix and 7% for cyclosporine A.
Danish: Andelen af patienter, der oplevede en organafstødning inden for et år, var 17 % for Nulojix og 7 % for cyclosporin A.
English: Nulojix is used in adults to prevent the body from rejecting a transplanted kidney.
Danish: Nulojix anvendes hos voksne for at forhindre kroppen i at afstøde en transplanteret nyre.
English: It suppresses the activity of ‘T cells', immune system cells that can become involved in organ rejection.
Danish: Det hæmmer aktiviteten af Tceller, som er immunsystemceller, der kan være involveret i organafstødning.
English: In two main studies involving 1,209 patients who underwent a kidney transplant, Nulojix was compared with cyclosporine A (another medicine used to prevent organ rejection).
Danish: I to hovedundersøgelser, der omfatter 1 209 patienter, som har gennemgået en nyreoperation, blev Nulojix sammenlignet med cyclosporin A (et andet lægemiddel, der bruges til at forhindre organafstødning).
English: In the first study, 97% of patients receiving Nulojix treatment survived with their kidneys intact (218 out of 226) compared with 93% of patients receiving cyclosporine A (206 out 221).
Danish: I den første undersøgelse overlevede 97 % af de patienter, der blev behandlet med Nulojix, med deres nyrer intakte (218 ud af 226) sammenlignet med 93 % af de patienter, der fik cyclosporin A (206 ud af 221).
English: Nulojix was shown to improve patient and organ survival following kidney transplantation.
Danish: Det blev påvist, at Nulojix forbedrer patient- og organoverlevelsen efter en nyretransplantation.
English: Around 54% of patients receiving Nulojix and 78% of those receiving cyclosporine A had impaired kidney function.
Danish: Ca. 54 % af de patienter, der fik Nulojix, og 78 % af dem, der fik cyclosporin A, havde nedsat nyrefunktion.
English: Nulojix is a powder that is made up into a solution for infusion (drip into a vein).
Danish: Nulojix er et pulver, der anvendes til at fremstille en infusionsvæske, opløsning (drop i en vene).
English: What is the risk associated with Nulojix?
Danish: Hvilken risiko er der forbundet med Nulojix?
English: For the full list of all side effects reported with Nulojix, see the package leaflet.
Danish: Den fuldstændige liste over alle de indberettede bivirkninger ved Nulojix fremgår af indlægssedlen.
English: Why has Nulojix been approved?
Danish: Hvorfor blev Nulojix godkendt?
English: What is Nulojix?
Danish: Hvad er Nulojix?
English: In the second study, 89% (155 out of 175) of patients on Nulojix and 85% (157 out 184) of those on cyclosporine A survived with their kidneys intact.
Danish: I den anden undersøgelse overlevede 89 % (155 ud af 175) af de patienter, der fik Nulojix, og 85 % (157 ud af 184) af dem, der fik cyclosporin A. Andelen af patienter, der havde nedsat nyrefunktion, var 77 % for de patienter, der fik Nulojix, og 85 % for de patienter, der fik cyclosporin A. Andelen af patienter, der oplevede en organafstødning inden for et år, var ca. 18 % for de patienter, der fik Nulojix, og 14 % for de patienter, der fik cyclosporin A.
English: What is Nulojix used for?
Danish: Hvad anvendes Nulojix til?
English: What benefit has Nulojix shown during the studies?
Danish: Hvilken fordel viser undersøgelserne, at der er ved Nulojix?
English: How has Nulojix been studied?
Danish: Hvordan blev Nulojix undersøgt?
English: How is Nulojix used?
Danish: Hvordan anvendes Nulojix?
English: How does Nulojix work?
Danish: Hvordan virker Nulojix?
English: ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
Danish: ANNEX I LISTE MED NAVNE, LÆGEMIDDELFORMER, STYRKER PÅ LÆGEMIDLERNE, ADMINISTRATIONSVEJ, INDEHAVER AF MARKEDSFØRINGSTILLADELSEN I MEDLEMSLANDENE
English: 170 09 Sverige (SWE)
Danish: 170 09 Sverige (SWE) Sweden
English: 152 32 Halandri, Athens
Danish: 152 32 Halandri, Athens Augmentin
English: Laboratórios Vitória, S.A. Rua Elias Garcia, 28Venda Nova
Danish: Laboratórios Vitória, S.A. Rua Elias Garcia, 28
English: Valeas S.p.A. via Vallisneri 10 20133 Milano
Danish: via Vallisneri 10 20133 Milano
English: Rua Dr. António Loureiro Borges, 3
Danish: Rua Dr. António Loureiro
English: United Kingdom Beecham Group PLC SB House
Danish: Storbritannien Beecham Group PLC SB House
English: Member State Marketing Authorisation (Invented) name
Danish: Indehaver af markedsføringstilladelsen
English: Glaxo Smith Kline B.V. Huis ter Heideweg 62 3705 LZ ZEIST THE NETHERLANDS
Danish: Huis ter Heideweg 62 3705 LZ ZEIST THE NETHERLANDS
English: Netherlands
Danish: THE NETHERLANDS
English: Augmentin (80 /11.97 mg/ml) 400/57mg/ 5ml Powder for oral suspension
Danish: Augmentin (80 /11.97 mg/ml) 400/57mg/ 5ml Pulver til oral suspension
English: Slovak Republic GlaxoSmithKline Slovakia sro., Galvaniho7/A, 82104
Danish: GlaxoSmithKline Slovakia sro., Galvaniho7/A, 82104 Bratislava, Slovakia.
English: Augmentin 125/31 SF Sachet 125/31.25mg Powder for oral suspension
Danish: Augmentin 125/31 SF Sachet 125/31.25mg Pulver til oral suspension
English: Clavamox Duo - Trockensaft 400/57mg/ 5 ml Powder for oral suspension
Danish: Clavamox Duo - Trockensaft 400/57mg/ 5 ml Pulver til oral suspension
English: amoxicilline/clavulaanzuur 250/62.5 mg Powder for oral suspension
Danish: amoxicilline/clavulaanzuur 250/62.5 mg Pulver til oral suspension
English: Stonemasons Way, Rathfarnham
Danish: Stonemasons Way, Rathfarnham Dublin 16
English: 2700-327 Amadora (Sob licença
Danish: Venda Nova 2700-327 Amadora (Sob licença GlaxoSmithKlineProdutos Farmacêuticos, Lda.)
English: Powder for injection
Danish: Pulver til injektionsvæsker
English: 1000/125 mg Powder for oral suspension
Danish: 1000/125 mg Pulver til oral suspension
English: 125/31.25mg/ 5mlOral suspension Oral use
Danish: 125/31.25mg/ 5mlOral suspension Oral
English: GlaxoSmithKline EOOD Ivan Vasov Complex Dimitar Manov street,
Danish: GlaxoSmithKline EOOD Ivan Vasov Complex Dimitar Manov street, bl.10, 1408 Sofia, Bulgaria
English: Dispersible tablets Oral use
Danish: Opløselige tabletter Oral
English: 250/31.25mg Powder for oral suspension
Danish: 250/31.25mg Pulver til oral suspension
English: 980 Great West Road Brentford, Middlesex, TW8
Danish: 980 Great West Road Brentford, Middlesex, TW8 9GS
English: Dispersible Tablet Oral use
Danish: Overtrukne tabletter Oral
English: Augmentin Intravenous 1.2g 1000/200 mg Powder for solution for injection or infusion
Danish: United Kingdom Augmentin Intravenous 1.2g 1000/200 mg Pulver til injektions- og infusionsvæsker,
English: Coated tablet
Danish: Filmovertrukken tablet
English: Powder for solution for injection AND Powder and solvent for solution for injection
Danish: Pulver til injektionsvæsker, opløsning OG pulver til infusionsvæser, opløsning
English: Luxembourg GlaxoSmithKline s.a. / n.v. Rue du Tilleul 13
Danish: Luxembourg GlaxoSmithKline s.a. / n.v.
English: Portugal
Danish: Portugall
English: 2000/200 mg Powder for infusionIntravenous use
Danish: 2000/200 mg Pulver til infusionsvæsker
English: Powder for injection or infusion
Danish: Pulver til injektions- og infusionsvæsker, opløsning
English: 1000/62.5 mg Modified release tablet
Danish: 1000/62.5 mg Tabletter med modificeret udløsning
English: 9GS UK
Danish: 9GS
English: 2000mg : 200mg/ vial
Danish: 2000mg : 200mg/ hætteglas
English: 1000/62.5mg modified-release tablet
Danish: 1000/62.5mg Tabletter med modiviceret udløsning
English: 1000/200 mg Powder for injection
Danish: 1000/200 mg Pulver til injektionsvæsker
English: 1000mg : 100mg/ vial
Danish: 1000mg : 100mg/ hætteglas
English: 1000/100 mg Powder for injection
Danish: 1000/100 mg Pulver til injektionsvæsker
English: 1000/62.5mg Film-coated tablet Oral use
Danish: 1000/62.5mg Filmovertrukne tabletter
English: 500mg : 50mg/ vial
Danish: 500mg : 50mg/ hætteglas
English: Beecham Group plc 980 Great West Road, Brentford, Middlesex TW8 9GS
Danish: Rumænien Beecham Group PLC 980 Great West Road, Brentford, Middlesex TW8
English: 1000/100 mg Powder for infusionIntravenous use
Danish: 1000/100 mg Pulver til infusionsvæsker
English: 1000/200 mg Powder for injection or infusion
Danish: 1000/200 mg Pulver til injektions- og infusionsvæsker, opløsning
English: Powder for solution for injection or infusion
Danish: Pulver til injections- og infusionsvæsker, opløsning
English: 1000/62.5mg Prolonged-release tablet
Danish: 1000/62.5mg Depottabletter
English: Powder for solution for infusion
Danish: Powder for oral suspension
English: This summary was last updated: 19/11/2010
Danish: Dette sammendrag blev sidst ajourført den 19/11/2010.
English: The benefit-risk balance may be found in module 6 of this EPAR.
Danish: Risk/benefit-forholdet fremgår af afsnit 6 i denne EPAR.
English: These side effects occur generally within the first week of treatment and are usually temporary and disappear once treatment has stopped.
Danish: Disse bivirkninger ses sædvanligvis inden for den første behandlingsuge og er i de fleste tilfælde forbigående og forsvinder ved behandlingens ophør.
English: Meloxoral contains the active substance meloxicam in a strength of 0.5 mg/ml (cats) or 1.5 mg/ml (dogs) for the oral suspension.
Danish: Meloxoral indeholder det aktive stof meloxicam i en styrke på 0,5 mg/ml (katte) eller 1,5 mg/ml (hunde) i den orale suspension.
English: People who are hypersensitive (allergic) to NSAIDs should avoid contact with Meloxoral.
Danish: Personer, som er overfølsomme (allergiske) over for NSAID'er, skal undgå kontakt med Meloxoral.
English: It can be used for both acute disorders, such as those seen after an injury, and chronic (long term) disorders.
Danish: Det kan anvendes både ved akutte lidelser, som for eksempel efter en skade, og kroniske (langvarige) lidelser.
English: Other information about Meloxoral:
Danish: Andre oplysninger om Meloxoral:
English: Meloxoral contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Danish: Meloxoral indeholder meloxicam, som tilhører en lægemiddelgruppe, der kaldes ikke-steroide antiinflammatoriske lægemidler (NSAID'er).
English: Studies looked at how Meloxoral was absorbed and its effects in the body, in comparison with Metacam.
Danish: I undersøgelser så man nærmere på, hvordan Meloxoral blev optaget i kroppen og på dets virkninger i kroppen sammenlignet med Metacam.
English: Therefore the CVMP's view was that, as for Metacam, Meloxoral's benefits are greater than its risks to alleviate inflammation and pain in musculo-skeletal disorders and they recommended that Meloxoral should be given a marketing authorisation.
Danish: Derfor var CVMP af den opfattelse, at ligesom det er tilfældet med Metacam, er fordelene ved Meloxoral større end risiciene, når det gælder lindring af betændelse og smerter ved lidelser i bevægeapparatet, og CVMP anbefalede, at der blev udstedt markedsføringstilladelse for Meloxoral.
English: Meloxoral is presented as a pale yellow oral suspension which is to be given mixed with food or directly into the mouth in dogs or cats.
Danish: Meloxoral er en lysegul oral suspension, som skal indgives opblandet i foder eller direkte i munden hos hunde eller katte.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Meloxoral to LeVet B.V. on 19/11/2010.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Meloxoral til LeVet B.V.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) considered that, in accordance with European Union requirements, Meloxoral has been shown to be bioequivalent to Metacam.
Danish: Udvalget for Veterinærlægemidler (CVMP) konkluderede, at det i overensstemmelse med EU-kravene er blevet påvist, at Meloxoral er bioækvivalent med Metacam.
English: prostaglandins are substances that trigger inflammation, pain, exudation and fever, meloxicam reduces those responses.
Danish: Da prostaglandinerne er de stoffer, der udløser betændelse, smerter, ekssudation og feber, mindsker meloxicam disse reaktioner.
English: Occasional side effects of Meloxoral are those seen with NSAIDs, such as loss of appetite, vomiting, diarrhoea, blood appearing in the stools, renal failure and apathy (lack of vitality).
Danish: De bivirkninger, der undertiden ses med Meloxoral, er de samme som dem, der normalt ses med NSAID'er, såsom nedsat appetit, opkastning, diarré, blod i afføringen, nyreinsufficiens og apati (mangel på vitalitet).
English: Meloxoral is a ‘generic' which means that Meloxoral is similar to a ‘reference veterinary medicine' already authorised in the EU (Metacam).
Danish: Meloxoral er et "generisk lægemiddel", hvilket betyder, at Meloxoral svarer til et "referenceveterinærlægemiddel", som allerede er godkendt i EU (Metacam).
English: Why has Meloxoral been approved?
Danish: Hvorfor blev Meloxoral godkendt?
English: Studies have been carried out to prove that Meloxoral is ‘bioequivalent' to the reference veterinary medicine which means that Meloxoral is equivalent to Metacam in the way it is absorbed and used by the body.
Danish: Der er gennemført undersøgelser for at påvise, at Meloxoral er "bioækvivalent" med referenceveterinærlægemidlet, hvilket betyder, at Meloxoral svarer til Metacam, når det gælder den måde, hvorpå det optages og virker i kroppen.
English: What is Meloxoral?
Danish: Hvad er Meloxoral?
English: How has the effectiveness of Meloxoral been studied?
Danish: Hvordan blev virkningen af Meloxoral undersøgt?
English: What is Meloxoral used for?
Danish: Hvad anvendes Meloxoral til?
English: In cats Meloxoral is used to alleviate inflammation and pain in chronic musculo-skeletal disorders.
Danish: Meloxoral anvendes til lindring af betændelse og smerter ved kroniske lidelser i bevægeapparatet hos katte.
English: What are the side-effects of Meloxoral?
Danish: Hvilke bivirkninger er der ved Meloxoral?
English: Meloxoral is used in dogs to relieve inflammation and pain in musculo-skeletal disorders.
Danish: Meloxoral anvendes til lindring af betændelse og smerter ved lidelser i bevægeapparatet hos hunde.
English: How does Meloxoral work?
Danish: Hvordan virker Meloxoral?
English: In the case of accidental ingestion medical advice should be sought immediately, showing the package leaflet or label to the physician.
Danish: Vis indlægssedlen eller etiketten til lægen.
English: The marketing authorisation was renewed on 24 March 2008.
Danish: Markedsføringstilladelsen blev fornyet den 24. marts 2008.
English: The company presented information from scientific articles already published on 90Y.
Danish: Virksomheden fremlagde informationer fra videnskabelige artikler, der allerede var offentliggjort om 90Y.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ytracis to CIS bio international on 24 March 2003.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Ytracis til CIS bio international den 24. marts 2003.
English: These may be substances such as antibodies that have been designed to recognise a particular type of cells in the body, including tumour cells.
Danish: Det kan være stoffer, såsom antistoffer, der er udviklet til at genkende en specifik type celler i kroppen, herunder tumorceller.
English: Other information about Ytracis:
Danish: Andre oplysninger om Ytracis:
English: A medicine labelled with Ytracis should not be used in women who are or may be pregnant.
Danish: Et lægemiddel, der er mærket med Ytracis, må ikke anvendes til kvinder, der er eller kan være gravide.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) YTRACIS EPAR summary for the public
Danish: EUROPÆISK OFFENTLIG VURDERINGSRAPPORT (EPAR) YTRACIS EPAR - sammendrag for offentligheden
English: It must be mixed outside the body, usually in a laboratory, with the medicine that needs radiolabelling.
Danish: Det skal blandes uden for kroppen, sædvanligvis i et laboratorium, med det lægemiddel, der skal mærkes radioaktivt.
English: Ytracis must not be given directly to any patient.
Danish: Ytracis må ikke gives direkte til patienten.
English: Ytracis will only be handled and given by people who have experience in the safe handling of radioactive material.
Danish: Ytracis må kun håndteres og gives af personer, der har erfaring i sikker håndtering af radioaktivt materiale.
English: It emits beta radiation.
Danish: Det udsender betastråling.
English: 90Y, yttrium-90, is a radioactive form of the chemical element yttrium.
Danish: 90Y, yttrium-90, er en radioaktiv form af det kemiske grundstof yttrium.
English: Ytracis is never given on its own.
Danish: Ytracis gives aldrig alene.
English: As Ytracis is a ‘precursor' and will not be given on its own, no studies have been done in humans.
Danish: Da Ytracis er en ‘prækursor' og ikke vil blive givet alene, er der ikke gennemført undersøgelser hos mennesker.
English: The Committee recommended that Ytracis be given marketing authorisation.
Danish: Udvalget anbefalede udstedelse af markedsføringstilladelse for Ytracis.
English: The company also presented published information supporting the use of 90Y in radiolabelling other medicines.
Danish: Virksomheden fremlagde endvidere offentliggjorte informationer, der støttede brugen af 90Y til radioaktiv mærkning af andre lægemidler.
English: The full EPAR for Ytracis is available here.
Danish: Den fuldstændige EPAR om Ytracis findes her.
English: The doctor who prescribes Ytracis must ensure that the risks linked to the radioactive exposure are lower than the risks from the disease itself.
Danish: Den læge, der ordinerer Ytracis, skal sikre, at risikoen fra strålingen er mindre end risikoen fra selve sygdommen.
English: As Ytracis is a precursor and will not be given on its own, it has no side effects.
Danish: Da Ytracis er en prækursor og ikke vil blive givet alene, har det ingen bivirkninger.
English: Ytracis is radioactive and its use may carry a risk of cancer and hereditary defects.
Danish: Ytracis er radioaktivt, og brugen af Ytracis kan indebære risiko for kræft og arvelige fejl.
English: What is the risk associated with Ytracis?
Danish: Hvilken risiko er der forbundet med Ytracis?
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Ytracis's benefits are greater than its risks for the radiolabelling of carrier molecules which have been specifically developed and authorised for radiolabelling with this radionuclide.
Danish: Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Ytracis er større end risiciene ved radioaktiv mærkning af bærermolekyler, som er specifikt udviklet og godkendt til radioaktiv mærkning med denne radionukleid.
English: Medicines radiolabelled with Ytracis should not be used in people who may be hypersensitive (allergic) to yttrium chloride or any of the other ingredients.
Danish: Lægemidler, der er radioaktivt mærkede med Ytracis, bør ikke anvendes til patienter, der kan være overfølsomme (allergiske) over for yttriumchlorid eller over for et eller flere af de øvrige indholdsstoffer.
English: The information supplied by the company supports the use of Ytracis as a precursor for radiolabelling medicines with 90Y.
Danish: De oplysninger, der er fremlagt af virksomheden, støtter brugen af Ytracis som en prækursor til radioaktiv mærkning af lægemidler med 90Y.
English: The active substance in Ytracis, yttrium (90Y) chloride, is a radioactive compound.
Danish: Det aktive stof i Ytracis, yttrium (90Y)-chlorid, er et radioaktivt stof.
English: An example of its use is the treatment of some types of tumours, where the radiolabelled medicine carries the radioactivity to the site of a tumour.
Danish: Et eksempel på brugen af Ytracis er behandling af visse typer tumorer, hvor det radioaktivt mærkede lægemiddel bærer radioaktiviteten hen til tumorstedet.
English: The 90Y contained in Ytracis then attaches itself to the carrier medicine and the resulting mixture is given according to the instructions in the Package Leaflet of the carrier medicine.
Danish: Det 90Y, der er indeholdt i Ytracis, sætter sig fast på det bærende lægemiddel, og den blanding, der herved dannes, indgives som anført i vejledningen på indlægssedlen for det bærende lægemiddel.
English: The quantity of Ytracis needed for radiolabelling and the quantity of the radiolabelled medicine that is given will depend on the medicine that is radiolabelled and the disease that is being treated.
Danish: Hvor stor en mængde Ytracis, der er nødvendig til radioaktiv mærkning, og hvor stor en mængde radioaktivt mærket medicin der gives, vil afhænge af det lægemiddel, der mærkes, og den sygdom, der behandles.